Seda Receives King’s Award for Enterprise

Medilink North of England member, Seda Pharmaceutical Development Services, receives the King’s Award for Enterprise 2024, having been honoured for its excellence in international trade.

The Stockport-based company has been awarded the King’s Award for Outstanding Short-Term Growth in overseas sales.

“We are absolutely delighted that Seda has been recognised with this most prestigious award” said Seda CEO, Dr Paul Stott. “It is a testament to the exceptional service underpinned by scientific excellence that our team consistently delivers, which has been the key driver of our recent growth. Global partnerships now account for more than half of our business and based on our increasing global reach and enhanced service offering, we expect that share to grow significantly over the coming years.”

Seda supports biotech clients in the design, development and market approval of novel medicinal products in a wide range of therapeutic areas.

The company has made significant investment in premises, equipment and in the expansion and development of the team to enhance its offering and meet client demand. In late 2024, it will open a neighbouring state-of-the art manufacturing facility to supply products for evaluation in clinical trials.

The King’s Awards for Enterprise programme, which was previously known as The Queen’s Awards for Enterprise, is now in its 58th year and is the most prestigious business award in the country. The awards celebrate the success of exciting and innovative businesses which are leading the way with pioneering products or services, delivering impressive social mobility programmes, or showing their commitment to excellent sustainable development practices.

This year 252 businesses have been recognised for their contribution to International Trade, Innovation, Sustainable Development and Promoting Opportunity (through Social Mobility). 

Successful businesses are then able to use the prestigious King’s Awards Emblem for the next five years.

For more information about Seda Pharmaceutical Development Services please visit